|
Dr. Mark Wedel is Senior Vice President of Development and Chief Medical Officer at Isis. He is responsible for clinical operations, strategic therapeutic portfolio management, and oversees all of Isis’ development programs including, cardiovascular, inflammatory, metabolic, infectious diseases, as well as oncology. Dr. Wedel joined Isis in 2001 from Alliance Pharmaceutical Corp. where he served as Director of Medical Affairs, Director of Pulmonary Therapeutics and consultant for the U.S. Department of Justice in its Health Care Fraud Division. Prior to that, Dr. Wedel was the Medical Director of the Medical/Surgical Intensive Care Unit, Green Hospital of the Scripps Clinic & Research Foundation as well as the Attending Intensivist, responsible for the care and treatment of critically ill patients, including post operative heart patients, liver transplants, respiratory cardiac, renal and hepatic failure.
Dr. Mark Wedel received his medical degree from The Johns Hopkins School of Medicine in Baltimore, Maryland; a J.D. from Thomas Jefferson School of Law, San Diego, California, and a B.A. from Valparaiso University, Valparaiso, Indiana. He is the author of more than 35 professional publications, member of 12 professional societies, including the American Medical Association, American College of Physicians, Society of Critical Care Medicine, the American Thoracic Society, and the American Academy of Pharmaceutical Physicians.
| 